Another biotech stock that insiders are jumping into here is Abbott Laboratories ( ABT), which is engaged in the discovery, development, manufacture and sale of a broad and a line of health care products. Insiders are buying this stock into modest strength, since shares are up 2.8% in the last months. Abbott Laboratories has a market cap of $53.82 billion and an enterprise value $58.26 billion. This stock trades at a reasonable valuation, with a trailing price-to-earnings of 9.15 and a forward price-to-earnings of 15.07. Its estimated growth rate for this year is -60.2%, and for next year it's pegged at 11.9%. This is not a cash-rich company, since the total cash position on its balance sheet is $11.50 billion and its total debt is $16.28 billion. A director just bought 10,000 shares, or about $338,000 worth of stock, at $33.83 to $33.86 per share. From a technical perspective, ABT is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last two months and change, with shares moving higher from its low of $29.84 to its recent high of $34.24 a share. During that uptrend, shares of ABT have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ABT within range of triggering a major breakout trade. Traders should now look for long-biased trades in ABT as long as it's trending above some near-term support levels at $32.55 or above its 50-day at $32.11, and then once it manages to break out above some key overhead resistance levels at $33.88 to $34.53 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 14.9 million shares. If that breakout triggers soon, then ABT will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside targets off that breakout are $37 to $40 a share.